The most selective GHRP available, stimulating GH release with minimal cortisol or prolactin elevation.
Molecular Weight
711.85 Da
Half-Life
~2 hours
Typical Dose
200–300 mcg
Cycle Length
8–16 weeks, with 4-week breaks
Description
Ipamorelin (NNC 26-0161) is a synthetic pentapeptide and one of the most selective growth hormone secretagogues ever developed. Discovered by Novo Nordisk in the 1990s, it was designed to maximize GH-releasing potency while minimizing off-target hormonal effects. Unlike earlier GHRPs such as GHRP-2 and GHRP-6, Ipamorelin does not significantly elevate cortisol, prolactin, or ACTH at standard doses, making it the preferred GHRP for long-term use. It is almost universally combined with CJC-1295 No DAC (a GHRH analog) to produce synergistic GH pulses through complementary receptor systems. Ipamorelin has completed Phase II clinical trials for post-operative ileus and has an excellent safety profile in human studies.
* Benefits based on preclinical/animal research unless otherwise noted.
Peptide Protocol Education Portal
Members-Only Access
Access advanced peptide education, protocol insights, and research-based information curated for informed users. Create a free account or log in to continue.
Please acknowledge the disclaimer above to continue.